Theranostics Australia is pleased to announce its partnership with the Pars Isotope Company as the Australian reference site for their Ge-68/Ga-68 generator. This partnership will facilitate the ongoing optimisation of this system for the preparation of Ga-68 labelled peptides and other agents, strengthening our commitment to the development of the highest quality diagnostic PET imaging techniques.
Private Theranostics Provider in Australia
We strive to develop and provide powerful innovative therapies
Established in May 2015, we are dedicated to continuously developing and utilising targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. Contact us today to find out more.
Our knowledge of how to treat cancer is the culmination of years of research, education and application of the most innovative developments in the field. Our team of specialists, supported by advanced technologies at our facilities, works tirelessly to offer the most innovative cancer treatments on the market.
For modern cancer treatment and a team of specialists who care about your wellbeing, contact us today.
Lutetium-177 Octreotate therapy is used to treat neuroendocrine tumours (NETs) that emerge from the endocrine or nervous system such as carcinoid tumours. It aims to reduce the size of the tumour(s) and stop them from multiplying, as well as to ease the associated symptoms. Read More
Lutetium-177 PSMA therapy is used for people with advanced prostate cancer. It is most often used when the disease has metastasised, and when other therapies are poorly tolerated or have failed. In certain patients, it can produce long-term remission. Read More
Radium-223 therapy is used for people who have prostate cancer that has spread to the bones. The therapy damages the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether. It is also used to reduce pain that can be associated with bone cancer. Read More
Iodine-131 therapy is a thyroid cancer treatment that uses radiation to treat either thyroid cancer or a hyperactive thyroid (thyrotoxicosis) by targeting the thyroid tissue. Read More
Yttrium-90 SIRT Therapy, or Selective Internal Radiation Therapy, is a treatment for cancers and tumours located within the liver. The aim of this treatment is to reduce the size of inoperable tumours or decrease the number of lesions in the liver. It may allow for the surgical removal of tumours, once considered inoperable. It may also stabilise the disease and prolong the life of the patient. Read More
Yttrium-90 Radiosynovectomy therapy is a treatment for painful joints caused by arthritis or other types of joint diseases, often providing relief for sufferers. Read More
Theranostics Australia is proud to announce the launch of our TA Portal, a securely encrypted web-based platform, allowing for efficient and effective information exchange between patients, referrers and Theranostics Australia staff from anywhere in the world.
For more information, visit: www.theranostics.com.au/patient-portal/
Theranostics Australia Celebrates Its 1 Year Anniversary.
Since our establishment in May 2015, Theranostics Australia has performed over 375 diagnostic Gallium-68 PET scans, and 60 Lutetium-177 therapy administrations since October 2015.
For more information, visit www.theranostics.com.au